Vertex Pharmaceuticals Stock Holdings Reduced by US Bancorp

Institutional investor US Bancorp DE cuts stake in biotech firm Vertex Pharmaceuticals by 8.1%

Mar. 3, 2026 at 12:07am

Got story updates? Submit your updates here. ›

According to a recent SEC filing, US Bancorp DE has reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.1% in the third quarter. The fund now owns 30,856 shares of the pharmaceutical company's stock, valued at $12,084,000 at the end of the reporting period.

Why it matters

Vertex Pharmaceuticals is a leading biotech firm focused on developing treatments for serious diseases like cystic fibrosis. Changes in institutional ownership can signal shifts in market sentiment and investor confidence around a company's prospects.

The details

US Bancorp DE sold 2,727 shares of Vertex Pharmaceuticals stock during the third quarter, reducing its total holdings to 30,856 shares. The firm cited the pharmaceutical company's stock performance and portfolio management decisions as reasons for the reduced stake. Vertex Pharmaceuticals' shares have risen over 35% in the past year as the company continues to advance its pipeline of CFTR modulators and other therapies.

  • US Bancorp DE filed the 13F report disclosing the reduced Vertex Pharmaceuticals stake in the third quarter of 2025.

The players

US Bancorp DE

A major institutional investor and asset management firm based in Minneapolis, Minnesota.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases like cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

The reduced stake by US Bancorp DE in Vertex Pharmaceuticals reflects the broader market dynamics around biotech stocks, where investors are closely monitoring pipeline progress, regulatory approvals, and commercial performance. However, Vertex remains a leader in the cystic fibrosis treatment space and continues to advance its research and development efforts.